Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

U.S.-Based PPD Inks Deal With Peking Biomedical, Expands Lab Services

This article was originally published in PharmAsia News

Executive Summary

U.S.-based Pharmaceutical Product Development inked an exclusive deal with Peking Union Lawke Biomedical Development Limited to expand its global central lab services in China, the company announced Jan. 23

You may also be interested in...



PPD Acquires China-based CRO Excel To Continue Global Expansion

SHANGHAI - The global contract research organization PPD has signed an agreement to acquire Excel PharmaStudies, a leading CRO in China, to upgrade its research capability across Asia, the company announced Oct. 27

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Table

View full table

Tags:
Latest Headlines

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

With One Launch Under Way, SpringWorks Ramps Up For A Second

Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar

Key Activist Investor Throws Shade At Novavax Over COVID-19 Vaccines

See All
UsernamePublicRestriction

Register

SC067851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By